Last reviewed · How we verify
NCT05933720
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
NA trial testing Polypeptides in Peripheral Arterial Occlusive Disease in 120 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Ryazan State Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 April 2023 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 September 2026 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Polypeptides — full drug profile →
- Femoral-popliteal bypass grafting with a synthetic graft above the knee
- Routine conservative treatment
Conditions studied
- Peripheral Arterial Occlusive Disease — all drugs for Peripheral Arterial Occlusive Disease →
Sponsor
Ryazan State Medical University
Who can join
Adults 18 to 80, any sex, with Peripheral Arterial Occlusive Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05933720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Arterial Occlusive Disease
Currently open trials in the same condition.
- NCT07352800 — Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-thr · Phase 2 · recruiting
Other Ryazan State Medical University trials
Trials by the same sponsor.
- NCT05920226 — Myocardial Fibrosis in Patients With Permanent Pacemakers · active not recruiting
- NCT06367166 — Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins · NA · active not recruiting
- NCT06806371 — PREDICTORS of CARDIOVASCULAR OUTCOMES in INDIVIDUALS with DIFFERENT OBESITY PHENOTYPES · active not recruiting
- NCT05899920 — Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to T · NA · recruiting
- NCT05455138 — Allografts in Surgery of the Main Arteries · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05933720 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ryazan State Medical University
- Last refreshed: 6 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05933720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing